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A B S T R A C T
Background/aims: In this multicentre study in clinical settings, we assessed the accuracy of optimized procedures
for FDG-PET brain metabolism and CSF classiﬁcations in predicting or excluding the conversion to Alzheimer's
disease (AD) dementia and non-AD dementias.
Methods: We included 80 MCI subjects with neurological and neuropsychological assessments, FDG-PET scan
and CSF measures at entry, all with clinical follow-up. FDG-PET data were analysed with a validated voxel-based
SPM method. Resulting single-subject SPM maps were classiﬁed by ﬁve imaging experts according to the disease-
speciﬁc patterns, as “typical-AD”, “atypical-AD” (i.e. posterior cortical atrophy, asymmetric logopenic AD var-
iant, frontal-AD variant), “non-AD” (i.e. behavioural variant FTD, corticobasal degeneration, semantic variant
FTD; dementia with Lewy bodies) or “negative” patterns. To perform the statistical analyses, the individual
patterns were grouped either as “AD dementia vs. non-AD dementia (all diseases)” or as “FTD vs. non-FTD (all
diseases)”. Aβ42, total and phosphorylated Tau CSF-levels were classiﬁed dichotomously, and using the
Erlangen Score algorithm. Multivariate logistic models tested the prognostic accuracy of FDG-PET-SPM and CSF
dichotomous classiﬁcations. Accuracy of Erlangen score and Erlangen Score aided by FDG-PET SPM classiﬁca-
tion was evaluated.
Results: The multivariate logistic model identiﬁed FDG-PET “AD” SPM classiﬁcation (Expβ=19.35, 95% C.I.
4.8–77.8, p < 0.001) and CSF Aβ42 (Expβ=6.5, 95% C.I. 1.64–25.43, p < 0.05) as the best predictors of
conversion from MCI to AD dementia. The “FTD” SPM pattern signiﬁcantly predicted conversion to FTD de-
mentias at follow-up (Expβ=14, 95% C.I. 3.1–63, p < 0.001). Overall, FDG-PET-SPM classiﬁcation was the
most accurate biomarker, able to correctly diﬀerentiate either the MCI subjects who converted to AD or FTD
dementias, and those who remained stable or reverted to normal cognition (Expβ=17.9, 95% C.I. 4.55–70.46,
p < 0.001).
Conclusions: Our results support the relevant role of FDG-PET-SPM classiﬁcation in predicting progression to
diﬀerent dementia conditions in prodromal MCI phase, and in the exclusion of progression, outperforming CSF
biomarkers.
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1. Introduction
Alzheimer's disease (AD) dementia and other neurodegenerative
dementias are preceded by a prodromal phase, namely mild cognitive
impairment (MCI), characterized by subtle clinical-neuropsychological
changes (Petersen et al., 2009), which are related to synaptic dys-
function and long-lasting pathological deposition of toxic proteins in
the brain (Pievani et al., 2014). MCI is characterized by objective
neuropsychological deﬁcits in one or more cognitive domains without
functional impairment in everyday life activities (Petersen et al., 2009).
Clinical longitudinal studies on MCI subjects provided evidence for
diﬀerent clinical outcomes, including conversion to AD or non-AD de-
mentias, to stabilization of cognitive proﬁle, or even reversion to
normal cognition (Mitchell and Shiri-Feshki, 2009; Petersen et al.,
2009). In the prodromal phase, the clinical-neuropsychological assess-
ment has limited accuracy for the prediction of conversion to AD de-
mentia (Löppönen et al., 2003; Storandt and Morris, 2010). To over-
come this limit, diagnostic biomarkers such as neuroimaging (i.e., MRI,
FDG-PET and amyloid-PET) and cerebrospinal ﬂuid-CSF (i.e., Aβ42,
total (t-Tau) and phosphorylated (p-Tau) Tau measures) have been in-
cluded in the current research criteria for “MCI due to AD” (Albert
et al., 2011). Among these biomarkers, the FDG-PET patterns of hy-
pometabolism seem to be particularly accurate in predicting conversion
from MCI to dementia, when compared to other biomarkers (Anchisi
et al., 2005; Bloudek et al., 2011; Dukart et al., 2015; Fellgiebel et al.,
2007; Landau et al., 2010; Perani et al., 2016; Prestia et al., 2013a;
Robb et al., 2017; Shaﬀer et al., 2013; Yuan et al., 2009). Notably, a
recent meta-analysis on a large sample of MCI (N=97) has shown that
adding FDG-PET imaging information to clinical data provides a better
prediction of conversion from MCI to dementia in comparison with
clinical data alone, with misclassiﬁcation rate dropping from 41.3%
(clinical data alone) to 27.2% (combined clinical and FDG-PET data)
(Shaﬀer et al., 2013). This study also showed that adding CSF and MRI
data does not signiﬁcantly improve clinical diagnosis.
However, the most recent Cochrane review on the use of FDG-PET
for the early diagnosis of AD dementia and other dementias in people
with MCI, concluded that there is no enough evidence to support the
use of FDG-PET in clinical routine, mainly due to a lack of standardized
and validated data analysis procedures (Smailagic et al., 2015). Another
paper by the European Association of Nuclear Medicine (EANM) stated
that even if a clear variability in diagnostic performance of FDG-PET is
reported in the literature, it is not attributable to the method itself, but
rather to a number of factors such as study design, deﬁnitions of MCI
and data analysis procedures (Morbelli et al., 2015). Thus, the lack of
validated and standardized methods for semi- or quantitative measures
to assess FDG-PET biomarker performance in diﬀerent clinical settings
seems to be the most important factor in producing the discrepancies in
the reported accuracy (see (Frisoni et al., 2013, 2017; Garibotto et al.,
2017; Perani, 2014; Prestia et al., 2013b)) and a consequent mismatch
in the proposed diagnostic algorithms (Albert et al., 2011; Dubois et al.,
2014; McKhann et al., 2011a). The use of validated semi-quantitative
methods and standardized operating procedures for the correct use of
neuroimaging biomarkers in research and clinical settings is indeed
strongly recommended by the international scientiﬁc societies, with the
aim to improve the diagnostic accuracy (Caroli et al., 2012; Frisoni
et al., 2013, 2017; Garibotto et al., 2017; Guerra et al., 2015; Mattsson
et al., 2017; Perani et al., 2014b).
SPM (Friston et al., 1994) is one of the most widespread methods to
statistically analyse voxel-wise FDG-PET data. A recently developed and
validated single-subject SPM procedure, takes advantage on a custom
FDG-PET dementia-speciﬁc template, and of a large normal dataset for
comparisons at the individual level, to obtain SPM t-maps with high
statistical accuracy (Della Rosa et al., 2014; Perani et al., 2014a). This
procedure allows the identiﬁcation of disease-speciﬁc brain hypome-
tabolism patterns at the single-subject level, outperforming both the
clinical characterization of patients and the visual qualitative
assessment of FDG-PET uptake images (Perani et al., 2014a). This op-
timized FDG-PET-SPM procedure provides patterns of brain hypome-
tabolism speciﬁc for each neurodegenerative condition (Caminiti et al.,
2017; Cerami et al., 2017; Perani, 2014; Perani et al., 2016), also in
prodromal phases (Cerami et al., 2015; Perani et al., 2014a, 2016).
The same issues apply to CSF biomarkers, with the Alzheimer's
Biomarkers Standardization Initiative stating that many factors (e.g.,
diagnostic procedures, samples processing and testing) challenge the
validity and comparability of CSF results among diﬀerent laboratories
(Vanderstichele et al., 2012).
FDG-PET imaging, as well as CSF markers, are considered useful for
the early diﬀerential diagnosis of AD vs. non-AD dementias (Gaugler
et al., 2013). These biomarkers reﬂect diﬀerent underlying brain
changes, namely neural injury and brain amyloid deposition (Blennow
et al., 2015; Perani, 2014). FDG-PET is a highly speciﬁc biomarker of
neurodegeneration, thus able to detect typical and atypical AD de-
mentia, as well as many non-AD dementia conditions, even in the
preclinical and prodromal phase (Arbizu et al., 2013; Bohnen et al.,
2012; Caroli et al., 2012; Cerami et al., 2015; Hinrichs et al., 2011;
Mosconi et al., 2008; Perani, 2014; Perani et al., 2016; Shaﬀer et al.,
2013; Teipel et al., 2015; Torosyan et al., 2017). On the other hand, CSF
Aβ42 can only provide information regarding the presence of brain
amyloidosis. Thus, even though low CSF Aβ42 levels well detect AD
dementia cases, discriminating them from frontotemporal dementia
(FTD) cases (Struyfs et al., 2015), reduced CSF Aβ42 concentrations
have been reported in many non-AD conditions (e.g., Parkinson's dis-
ease, dementia with Lewy bodies, vascular dementia) (Blennow et al.,
2005; Kaerst et al., 2014; Stefani et al., 2012). Concerning CSF Tau,
increased concentrations of both t-Tau and p-Tau support the diagnosis
of AD dementia. However, especially at the individual level, there is
excessive overlap between Tau levels of patients with AD dementia and
other dementias and even with controls, thus undermining its potenti-
ality as an accurate biomarker (van Harten et al., 2011). This overlap in
CSF levels essentially limits the use of CSF as a unique biomarker for
diﬀerential diagnosis.
The combined use of biomarkers for neuronal dysfunction (e.g.,
FDG-PET or CSF Tau levels) and amyloidosis (e.g., CSF Aβ42 levels),
assessed with validated and standardized procedures, is expected to
improve their diagnostic eﬀectiveness, also providing complementary
information. Notwithstanding the increasing use of these biomarkers in
research and clinical settings, available works in MCI populations,
combining FDG-PET and CSF markers, are limited and strictly focused
on conversion to AD dementia (Chen et al., 2016; Choo et al., 2013;
Galluzzi et al., 2013; Gomar et al., 2014; Landau et al., 2010; Prestia
et al., 2013a; Shaﬀer et al., 2013; Walhovd et al., 2010; Young et al.,
2013). Since AD dementia constitutes only one of the possible clinical
outcomes for MCI condition (Mitchell and Shiri-Feshki, 2009), data on
validated biomarker accuracy for risk progression to diﬀerent de-
mentias in a large prodromal MCI sample are necessary, and currently
lacking.
Here, we assessed the accuracy of FDG-PET using an optimized
voxel-based procedure (Cerami et al., 2015; Della Rosa et al., 2014;
Perani et al., 2014a, 2016) and CSF (i.e., Aβ42, t-Tau and p-Tau) bio-
markers in the prediction of conversion to AD and non-AD dementias in
a large sample of MCI belonging to diﬀerent clinical centres. The aim of
this multicentre study was to evaluate the individual and combined
performance of the biomarkers in the risk prediction or, notably, in the
exclusion of conversion to AD and non-AD dementia conditions.
2. Materials and methods
2.1. Patients
We retrospectively collected clinical and biomarker information in
80 MCI subjects belonging to a large database resulting from a colla-
borative multicentre Italian study on neurodegenerative dementias. The
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criteria for retrospective inclusion were as follows: (1) a clinical diag-
nosis of MCI at baseline, made in accordance with Petersen criteria
(Petersen et al., 2009); (2) Washington University Clinical Dementia
Rating (CDR) scale= 0.5 (Hughes et al., 1982); (3) detailed clinical,
neuropsychological and neurobehavioral assessment at baseline; (3)
FDG-PET imaging performed within 6 months from baseline; (4) CSF
Aβ42, t-Tau and p-Tau measurement; (4) clinical follow-up. The ex-
clusion criteria were (1) presence of neoplastic or signiﬁcant cere-
brovascular lesions; (2) neurosurgery or other neurological conditions,
including epilepsy, encephalitis or stroke (3) clinically relevant psy-
chiatric disorders, in accordance with DSM-IV criteria; (4) current or a
recent history of drug or alcohol abuse/dependence.
According to Petersen criteria (Petersen et al., 2009), the included
MCI subjects were classiﬁed at baseline as either single-domain am-
nestic (aMCI n=31), or non-amnestic (naMCI n=8), or multi-domain
amnestic (md aMCI n= 35) or non-amnestic (md naMCI n= 6) MCI. At
follow-up, MCI subjects could either (1) meet criteria for a diagnosis of
dementia (Armstrong et al., 2013; Gorno-Tempini et al., 2011; Litvan
et al., 1996; McKeith et al., 2017; McKhann et al., 2011a; Rascovsky
et al., 2011); (2) still fulﬁl criteria for MCI (Petersen et al., 2009) or (3)
have reverted to normal cognition.
Expert neurologists and neuropsychologists provided data on pa-
tients' history, neurological and neuropsychological status, and clinical
assessment at follow-up (19.4 ± 10.1 months). The diagnosis at
follow-up was obtained according to the current diagnostic criteria for
each dementia type (Armstrong et al., 2013; Gorno-Tempini et al.,
2011; Litvan et al., 1996; McKeith et al., 2017; McKhann et al., 2011a;
Rascovsky et al., 2011), and constituted the reference standard for the
present study.
The study was conducted in accordance with the provisions of the
Helsinki Declaration and was approved by the Ethic Committee of each
centre. Written informed consent was obtained from each participant.
2.2. CSF acquisition and analysis
CSF was obtained by lumbar puncture in the L3-L4 or L4-L5 inter-
space from all the included MCI subjects. The procedure was always
performed early in the morning. No serious adverse events were re-
ported. The CSF sample (8–10ml) was collected in sterile poly-
propylene tubes: part of it was used to determine routine chemical
parameters (leucocyte and erythrocyte cell count, glucose measure-
ment, protein total content) and the remaining CSF was centrifuged for
10 min at 4000g at 4 °C. The aliquots were then stored at −80 °C until
analysis, to ensure the stability of the CSF biomarkers. Measurement of
CSF Aβ42, Tau, and p-Tau was performed using commercially available
ELISA kit according to the manufacturer's protocol and blinded to
clinical diagnoses.
2.3. FDG-PET acquisition and processing
FDG-PET scan acquisitions were performed in each centre following
standardized procedures, in compliance with the European Association
of Nuclear Medicine (EANM) guidelines (Varrone et al., 2009). Before
radiopharmaceutical injection, subjects were fasted for at least six
hours to ensure measured blood glucose level was< 120mg/dl. Static
emission images were acquired starting 30–45 min after injecting
185–250MBq of [18F]FDG via a venous cannula. This post-injection
time interval allows to obtain an equal distribution of the tracer across
the entire brain, with negligible blood ﬂow-dependent diﬀerences, thus
achieving an optimal signal-to-noise ratio (Signorini et al., 1999). Static
acquisition scan duration ranged from 10 to 15min. PET images were
reconstructed using an ordered subset expectation maximization
(OSEM) algorithm. Attenuation correction was based on the software
provided by the manufacturer integrated in each scanner. The following
CT scans provided the FDG-PET images: Discovery GE Healthcare ST
PET/CT (Perugia), Discovery GE Healthcare STE PET/CT (San Raﬀaele
Hospital, Milan), Byograph mCT PET/CT (Brescia), Byograph Truepoint
64 PET/CT (Policlinico, Milan) and Siemens Hirez PET/CT (Genoa).
Image analysis was centralized and performed at San Raﬀaele
Hospital (Milan) according to a voxel-based Statistical Parametrical
Mapping (SPM) procedure at the single-subject level previously vali-
dated in dementias (Della Rosa et al., 2014; Perani et al., 2014a, 2016).
Notably, since this voxel-based SPM procedure provided optimal re-
liability with diﬀerent scanners (Presotto et al., 2017), it was equally
applied to these multicentre FDG-PET data.
2.4. Biomarker analysis
2.4.1. CSF
CSF biomarker variables included Aβ42, t-Tau, and p-Tau (i.e.
phosphorylated at threonine 181 or p-Tau181p) levels in ng/L, as well
as ratios (t-Tau/Aβ42 and p-Tau/Aβ42). Each CSF measure was di-
chotomously classiﬁed as positive or negative for AD according to va-
lidated cut-oﬀ values: CSF Aβ42 values≥ 500 ng/l, t-Tau≤ 450 ng/l
and p-Tau≤ 61 ng/l (Sjogren et al., 2001).
We further classiﬁed the CSF measures following the Erlangen Score
Diagnostic Algorithm. According to this algorithm, the CSF measures
were scored into ﬁve groups, covering all possible CSF data combina-
tions. The scores range from 0, if all CSF biomarkers were normal, to
1–3 points reﬂecting intermediate CSF abnormality, and up to 4 points,
when frank abnormalities in Aβ42 pathology and t-Tau or p-Tau were
detected (Lewczuk et al., 2009).
2.4.2. FDG-PET-SPM classiﬁcation
Each subject image was (1) evaluated for accuracy in acquisition
and reconstruction; (2) normalized to a FDG-PET speciﬁc template
(Della Rosa et al., 2014); (3) tested for relative “hypometabolism” on a
voxel-by-voxel basis by means of a two-sample t-test (i.e., 1 patient vs.
112 healthy control subjects), entering age as a nuisance covariate
(Perani et al., 2014a). Threshold was set at p < 0.05, FWE-corrected
for multiple comparisons at the voxel level. Only clusters with>100
voxels were deemed signiﬁcant.
Each FDG-PET-SPM hypometabolic pattern was classiﬁed by 5 in-
dependent neuroimaging experts, blinded to clinical-neuropsycholo-
gical and CSF information. The raters had to make a forced decision
among diﬀerent options: 1) ‘AD’ patterns (i.e., ‘typical-AD’ (McKhann
et al., 2011a) and ‘atypical-AD’ patterns, namely the asymmetric pat-
tern of the logopenic variant of AD (Gorno-Tempini et al., 2011), the
posterior cortical atrophy pattern (PCA) (Cerami et al., 2016), and the
frontal-AD pattern (Kalpouzos et al., 2005)); 2) ‘FTD’ patterns (e.g., the
behavioral variant of frontotemporal dementia (bvFTD) pattern
(Rascovsky et al., 2011), the corticobasal degeneration pattern (CBD)
(Armstrong et al., 2013); the progressive supranuclear palsy (PSP)
pattern (Litvan et al., 1996), the semantic variant FTD pattern (Drzezga
et al., 2008); 3) the dementia with Lewy bodies (DLB) pattern (McKeith
et al., 2017) and 4) the negative pattern (i.e., no statistical signiﬁcant
hypometabolism in the comparison with normal controls). The in-
dependent classiﬁcations performed by each rater were merged into a
single variable (i.e., the FDG-PET-SPM classiﬁcation), consisting in the
classiﬁcation performed by the majority of raters. The Cohen's k coef-
ﬁcient was used to evaluate the inter-raters agreement.
The Erlangen Score Diagnostic Algorithm was aided by FDG-PET-
SPM classiﬁcation when the cases were classiﬁed according to the
Erlangen Score Diagnostic Algorithm as 1=AD improbable; 2=AD
possible; 3=AD possible, thus with uncertainty. The FDG-PET-SPM
classiﬁed these cases as either AD or non-AD, according to the speciﬁc
pattern of hypometabolism. Patients' classiﬁcation was modiﬁed ac-
cording only to the FDG-PET-SPM classiﬁcation.
2.5. Statistical analyses
ANOVA (with Bonferroni post-hoc correction) and Pearson's Chi-
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squared tests were used to assess diﬀerences across MCI sub-classiﬁ-
cations (i.e. aMCI and naMCI single and multi-domain) on baseline
sociodemographic variables (age, gender and education), disease se-
verity (MMSE score), CSF measures and FDG-PET-SPM classiﬁcation.
We then assessed the association between the clinical progression at
follow-up and the following variables: I) baseline MCI sub-classiﬁca-
tion; II) FDG-PET-SPM classiﬁcation; III) CSF measures. We used
ANOVA with Bonferroni post-hoc correction for continuous variables
(CSF measures), and Pearson's Chi-squared test for dichotomous vari-
ables (CSF Aβ42, t-Tau and p-Tau positivity, MCI sub-classiﬁcation (i.e.,
aMCI and naMCI), and FDG-PET-SPM classiﬁcation (i.e., ‘AD’ and ‘non-
AD’ patterns). Then, we assessed the concordance between each CSF
biomarker positivity/negativity and the Erlangen Score with FDG-PET-
SPM classiﬁcation, using Pearson's Chi-squared test.
2.5.1. AD vs. non-AD predictive model
We considered measures of sensitivity, speciﬁcity, positive and ne-
gative likelihood ratios (LR+ and LR−) and overall accuracy (AUC) for
assessing the diagnostic classiﬁcation accuracy of CSF Aβ42, t-Tau and
p-Tau positivity, CSF t-Tau/Aβ42 and p-Tau/Aβ42 ratios, Erlangen
Score, FDG-PET-SPM classiﬁcation and Erlangen Score aided by FDG-
PET-SPM classiﬁcation in the prediction of MCI conversion to AD de-
mentia. We tested the AUCs diﬀerences between biomarkers using the
non-parametric DeLong test for paired samples (DeLong et al., 1988).
Further, we estimated the predictive power of FDG-PET-SPM classiﬁ-
cation and CSF biomarkers separately, through two diﬀerent logistic
regression models, with diagnosis at follow-up (AD-nonAD) as depen-
dent variable. Variables signiﬁcantly predicting progression in the se-
parate models were then jointly assessed in a multivariate stepwise
logistic regression analysis. Reliability of multivariate logistic regres-
sion models was assessed by means of a bootstrap resampling proce-
dure, in which the logistic regression analysis was reiterated 1000
times.
2.5.2. FTD vs. non-FTD predictive model
Being meant to establish the presence (or absence) of AD patho-
physiological processes only, CSF biomarkers were not included in the
FTD vs. non-FTD biomarkers' predictive accuracy analysis. Thus, we
assessed the predictive accuracy in FTD vs. non-FTD conversion of FDG-
PET-SPM classiﬁcation only. As above, we considered measures of
sensitivity, speciﬁcity, LR+ and LR- and overall accuracy (AUC). We
estimated the predictive power of FDG-PET-SPM classiﬁcation through
a logistic regression model including diagnosis at follow-up (FTD-
nonFTD) as dependent variable. A bootstrap resampling procedure was
performed to assess logistic regression reliability.
The statistical analyses were performed with SPSS for Windows
(Statistical Package for Social Sciences, IBM, Armonk, New York, USA,
Version 23).
In order to provide further assessment of the predictive value of
FDG-PET biomarker’ performance, we took into account alternative
independent follow-up outcomes. We considered CDR scores at follow-
up, as a measure of dementia conversion. We tested concordance be-
tween FDG-PET-SPM classiﬁcation and CDR, by means of Pearson's Chi-
squared test. Further, we tested FDG-PET-SPM classiﬁcation predictive
value using a logistic regression model.
3. Result
3.1. MCI progression at follow up
MCI subgroups did not show diﬀerences in sociodemographic
variables (Table 1). Of note, the clinical MCI classiﬁcation (Petersen
et al., 2009) was not associated with speciﬁc FDG-PET-SPM or CSF
patterns.
At follow-up, 50 out of 80 MCI subjects developed dementia,
namely 39 converted to AD dementia, 10 to dementia within the FTD
spectrum and 1 to DLB, while 27 remained stable and 3 reverted to
normal cognition (Table 2).
Out of 39 MCI who converted to AD, 28.2% were single-domain
aMCI (11), 56.4% multi-domain aMCI (22), 12.8% single-domain
naMCI (5), and 2.6% multidomain naMCI (1). Three multi-domain
naMCI, 4 single-domain and 3 multi-domain aMCI subjects converted to
FTD. One multi-domain a-MCI converted to DLB. Two single-domain
aMCI and one multidomain naMCI subjects returned to cognitive nor-
mality (i.e. classiﬁed as reverters). The remaining subjects were stable
at the follow-up visit.
3.2. CSF measures
At baseline, the Aβ42 CSF concentration was signiﬁcantly lower in
the MCI who converted to AD dementia as compared to cognitively
stable and FTD converter subjects. In addition, p-Tau, t-Tau/Aβ42 and
p-Tau/Aβ42 ratios were all signiﬁcantly increased in the AD converters
(Table 2). The 52.1% of MCI cases with “normal” CSF, remained stable
or reverted to normal cognition at follow-up, the remaining 47.9% MCI
with ‘normal’ CSF, converted to dementia (Table 2).
As for Erlangen Score, 14 out of 39 MCI who converted to AD
showed Aβ42 and Tau measures within the Erlangen Score= 4. The
majority of stable (21 out of 27) and reverter (3 out of 3) MCI subjects,
showed Erlangen Scores≤2. The MCI with intermediate score levels (1
to 3) progressed to AD dementia in 25 out of 39 cases and to FTD de-
mentia in 6 out of 10 cases, remained stable in 10 out of 27 cases,
reverted in 1 out of 3 cases.
3.3. FDG-PET-SPM classiﬁcation
Since we found a good agreement among the ﬁve experts in the
FDG-PET-SPM classiﬁcation (Cohen's k= 0.82), we merged the in-
dependent classiﬁcations into a single variable. The expert raters
identiﬁed the following FDG-PET-SPM patterns, suggestive of diﬀerent
neurodegenerative conditions according to the previous literature: 43
AD typical and atypical-AD patterns (i.e., 15 typical AD, 6 frontal-AD,
13 asymmetric logopenic AD variant and 9 PCA); 17 FTD patterns (i.e.,
11 bv-FTD, 3 semantic variants, 2 CBD, and 1 PSP); 1 DLB pattern and
19 negative patterns (see Supplementary Fig. 1 for FDG-PET-SPM pat-
terns examples). A signiﬁcant association was found between AD, DLB
and FTD FDG-PET-SPM patterns classiﬁcation and, respectively, AD
dementia, DLB and FTD conversions at follow-up (Table 2). FDG-PET-
SPM classiﬁcation identiﬁed 14 MCI subjects with hypometabolism
patterns speciﬁc for dementias but showing cognitive stability at
follow-up, namely 5 AD and 9 FTD patterns. None of them reverted to
normal cognition (Table 2). In addition, there were 16 negative FDG-
PET-SPM patterns that accurately predicted stable condition or rever-
sion to normal cognition (Table 2). Three MCI cases with negative FDG-
PET-SPM patterns that were diagnosed as AD dementia at follow-up
showed unspeciﬁc hypometabolic patterns, suggestive of underlying
minor cerebrovascular pathology (Heiss et al., 1986).
3.4. FDG-PET-SPM patterns and CSF association
We found a signiﬁcant association (high concordance) between
FDG-PET-SPM AD patterns and CSF Aβ42, t-Tau and p-Tau positivity
for AD pathology (p < 0.05); the presence of FDG-PET-SPM FTD pat-
terns was instead associated with negative CSF Aβ42, positive p-Tau
and t-Tau levels and Erlangen Scores of 0, 1, 2. In details, 10/17 cases
had Erlangen Score equal to 0, indicative of non-AD pathology; 1/17
cases had Erlangen Score equal to 1, indicative of improbable AD; 6/17
cases had Erlangen Score equal to 2, suggesting possible AD (see
Table 3 and Fig. 1). No signiﬁcant diﬀerence in CSF biomarkers was
found between typical and atypical AD FDG-PET-SPM patterns (Sup-
plementary Fig. 2).
Concerning the stable or reverter cases with FDG-PET-SPM negative
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pattern (n= 13 and n= 3, respectively) we found, as for CSF measures,
9 cases with pathological values of either of Aβ42, p-Tau, t-Tau and
Erlangen Score > 0.
3.5. AD dementia vs. non-AD dementia predictive model
The CSF dichotomous classiﬁcations provided the following levels
of accuracy in the prediction of conversion to AD dementia: Aβ42
AUC=0.77 (95% C.I. 0.67–0.88, p < 0.001); t-Tau AUC=0.61 (95%
C.I. 0.48–0.73, p=0.10); p-Tau AUC=0.67(95% C.I. 0.55–0.79,
p=0.01); t-Tau/Aβ42 ratio AUC=0.81 (95% C.I. 0.72–0.91,
p < 0.001), with the highest level of accuracy provided by the p-Tau/
Aβ42 ratio AUC=0.84 (95% C.I. 0.75–0.93, p < 0.001). The Erlangen
Score (≥3) provided an AUC equal to 0.81 (95% C.I. 0.71–0.91,
p < 0.001) in the prediction of AD dementia conversion.
FDG-PET-SPM classiﬁcation showed the best accuracy in the pre-
diction of conversion to AD dementia AUC=0.85 (95% C.I. 0.76–0.94,
p < 0.001).
The Erlangen Score aided by FDG-PET-SPM classiﬁcation, allowed
to correctly classify AD dementia converters in 35 out of 39 cases,
providing an AUC equal to 0.82 (95% C.I. 0.73–0.92, p < 0.001).
We found that AUC for FDG-PET-SPM classiﬁcation was not statis-
tically diﬀerent from CSF Aβ42 (Z=1.35, p= 0.18), t-Tau/Aβ42 ratio
(Z=0.63, p=0.53) and p-Tau/Aβ42 ratio (Z= 0.17, p= 0.86). This
indicates the important role of these CSF biomarkers in AD diagnosis.
Of note, AUC for FDG-PET-SPM classiﬁcation was signiﬁcantly higher
than CSF t-tau AUC (Z=4.08, p < 0.001) and CSF p-tau AUC
(Z=2.97, p < 0.005). No signiﬁcant diﬀerence was found between
Table 1
Sociodemographic, clinical and biomarkers measures divided by MCI sub-type at baseline.
SAMPLE Total aMCI NaMCI md aMCI md naMCI p-value
N 80 31 8 35 6 –
Gender M/F 37/43 17/14 5/3 13/22 2/4 ns
Age (years) Mean 70.03 70.39 73.05 69.81 65.33 ns
SD 7.29 6.29 8.92 7.08 10.61
Education (years) Mean 9.69 10.50 9.75 9.44 6.67 ns
SD 3.84 4.13 4.68 3.40 2.16
MMSE Mean 25.60 25.93 25.79 25.18 26.03 ns
SD 2.73 2.81 3.16 2.62 2.66
Aβ42 < 500 (ng/l) Mean 562.76 609.81 498.38 510.74 701.09 ns
SD 289.39 333.97 317.16 225.76 313.63
t-Tau > 450 (ng/l) Mean 488.40 534.84 546.39 460.31 332.63 ns
SD 375.10 414.30 193.56 394.39 152.06
p-Tau > 61 (ng/l) Mean 70.77 78.07 94.18 61.61 52.50 ns
SD 35.69 36.23 39.55 32.79 22.49
t-Tau/Aβ42 Mean 1.16 1.26 1.41 1.12 0.54 ns
SD 1.07 1.19 0.77 1.08 0.34
p-Tau/Aβ42 Mean 0.17 0.19 0.26 0.14 0.09 ns
SD 0.13 0.15 0.17 0.11 0.04
FDG SPM AD n 43 14 5 22 2 ns
FDG SPM FTD n 17 9 2 5 1 ns
FDG SPM DLB n 1 0 0 1 0 ns
FDG SPM negative n 19 8 1 7 3 ns
Abbreviations: MCI=mild cognitive impairment, aMCI= amnestic (single-domain) MCI, md aMCI=multi-domain amnestic MCI, naMCI=non-amnestic (single-domain) MCI, md
naMCI=multi-domain non-amnestic MCI, SD= standard deviation, AD=Alzheimer's disease, FTD= frontotemporal lobar degeneration, DLB=dementia with Lewy bodies,
n= number. Statistical diﬀerences were assessed performing ANOVA and Chi-square analyses.
Table 2
Biomarkers measures compared according to the clinical conversion at follow-up.
SAMPLE AD FTD DLB Stable Reverter Total P-value
N 39 10 1 27 3 80 –
CSF Aβ42 (ng/l) Mean 416.4* 750.3 200 721.7 578.7 562.7 <0.001
SD 194.9 233.8 – 319.7 152.7 289.4
Positive < 500 (ng/l) N 31* 1 1 8 1 42 <0.05
CSF t-Tau (ng/l) Mean 595.7 479.7 521.0 367.0 180.0 488.8 ns
SD 448.9 351.1 – 209.4 46.2 375.1
Positive > 450 (ng/l) N 21* 4 1 9 0 35 <0.05
CSF p-Tau (ng/l) Mean 83.8* 64.7 59.0 56.6 45.3 70.8 0.01
SD 34.9 40.8 – 30.1 5.1 35.7
Positive > 61 (ng/l) N 29* 5 0 11 0 45 <0.05
CSF p-Tau/Aβ42 ratio Mean 0.2* 0.1 0.3 0.1 0.08 0.17 <0.01
SD 0.14 0.06 – 0.1 0.01 0.13
CSF t-Tau/Aβ42 ratio Mean 1.6* 0.7 2.6 0.7 0.3 1.2 <0.05
SD 1.2 0.5 – 0.63 0.01 1.1
FDG-PET ‘AD’ pattern N 35* 3 0 5 0 43 <0.05
FDG-PET ‘FTD’ pattern N 1 7* 0 9* 0 17 <0.05
FDG-PET “DLB” pattern N 0 0 1* 0 0 1 <0.05
FDG-PET ‘negative’ pattern N 3 0 0 13* 3* 19 <0.05
Abbreviations: CSF= cerebrospinal ﬂuid; t-Tau= total Tau; p-Tau= phosphorylated Tau; AD=Alzheimer's disease, FTD= frontotemporal dementia, DLB=dementia with Lewy
bodies. Statistical diﬀerences were assessed performing ANOVA and Chi-square analyses.
* Signiﬁcance at p < 0.05.
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FDG-PET SPM classiﬁcation AUC and Erlangen Score AUC (Z= 1.023,
p=0.31) as well as between FDG-PET SPM classiﬁcation AUC and
Erlangen Score aided by FDG-PET SPM classiﬁcation AUC (Z= 1.36,
p=0.18).
In addition, AUC for Aβ42 was signiﬁcantly higher than AUC for t-
tau (Z= 2.43, p < 0.05), whereas AUCs for both t-Tau/Aβ42 ratio and
p-Tau/Aβ42 ratio were signiﬁcantly higher than AUC for t-tau
(Z=6.897, p < 0.001; Z=5576, p < 0.001, respectively) and p-tau
(Z=2.83, p < 0.01; Z= 3.97, p < 0.001, respectively).
As for Erlangen Score and Erlangen Score aided by FDG-PET-SPM
classiﬁcation, the corresponding AUCs were signiﬁcantly higher than
AUCs for CSF t-tau (Z=4.056, p < 0.001; Z= 3.826, p < 0.001,
respectively) and p-tau (Z= 2.165, p < 0.05; Z=2.347, p < 0.05,
respectively).
LR+ and LR− values are represented for each biomarker in Fig. 2.
Considering the logistic regression models, in the CSF biomarkers
model, Aβ42 (Expβ=11.4, 95% C.I. 3.6–36, p < 0.01) and p-Tau CSF
positivity (Expβ=5.2, 95% C.I. 1.5–17.7, p < 0.01) signiﬁcantly
predicted conversion to AD dementia; the model with FDG-PET ‘AD’
SPM classiﬁcation signiﬁcantly predicted conversion to AD dementia
(Expβ=36.1, 95% C.I. 9.9–131.2, p < 0.001). The multivariate lo-
gistic model identiﬁed FDG-PET ‘AD’ SPM classiﬁcation (Expβ=19.35,
95% C.I. 4.8–77.8, p < 0.001) and CSF Aβ42 (Expβ=6.5, 95% C.I.
1.64–25.43, p < 0.05) as the best predictors of the conversion from
MCI to AD dementia. This predictive model was signiﬁcantly more ef-
fective than the null one (χ2= 52.82, p < 0.001) in the prediction of
conversion to AD dementia at follow-up. Results were conﬁrmed at
bootstrap resampling.
3.6. FTD vs. non-FTD predictive model
FDG-PET-SPM classiﬁcation showed a good accuracy in the pre-
diction of conversion to FTD AUC=0.78 (95% C.I. 0.60–0.95,
p=0.005).
Concerning the logistic regression model for the FDG-PET-SPM
classiﬁcation, the ‘FTD’ SPM classiﬁcation signiﬁcantly predicted con-
version to FTD at follow-up (Expβ=14, 95% C.I. 3.1–63, p < 0.001).
Results were conﬁrmed at bootstrap resampling.
We found high concordance between FDG-PET evidence of neuro-
degeneration and CDR (Chi-squared= 23.197, p < 0.001).Consistent
with reported results using clinical diagnosis at follow-up as gold
standard, FDG-PET-SPM maps signiﬁcantly predicted dementia con-
version according to CDR (Expβ=17.9, 95% C.I. 4.55–70.456,
p < 0.001). This suggests limited bias due to the circularity and con-
ﬁrms the overall robustness in the reported results.
4. Discussion
In MCI, the neuropsychological information and the derived sub-
classiﬁcation is poorly accurate in predicting the conversion to diﬀerent
dementias (Löppönen et al., 2003; Storandt and Morris, 2010). Notably,
in our cohort, both aMCI and naMCI converted to AD and non-AD de-
mentias, in line with previous studies (Fischer et al., 2007; Ravaglia
et al., 2005).
In this study, we aimed at assessing the role of CSF and FDG-PET
biomarkers, individually and combined, in the prediction of conversion
to dementia in a large multicentre cohort of MCI subjects. Both bio-
markers are considered as supporting information for AD dementia
diagnosis (McKhann et al., 2011a), and, in MCI condition for early
detection of AD (Albert et al., 2011).
FDG-PET-SPM classiﬁcation and CSF Aβ42 positivity, both in-
dividually and combined, signiﬁcantly predicted the conversion from
MCI to AD dementia at follow-up. These data align well with recent
ﬁndings showing that CSF Aβ42 is a reliable biomarker for AD de-
mentia, diﬀerentiates patients from healthy controls and detects MCI
subjects who will convert to AD dementia (Olsson et al., 2016; Tang
et al., 2014).
Of note, in the present study, the p-Tau/Aβ42 ratio showed good
accuracy in predicting MCI conversion to AD dementia (Fig. 2). This
result is also consistent with previous studies, in which the p-Tau/Aβ42
ratio was found to be the most accurate CSF measure for predicting MCI
conversion to AD dementia (Landau et al., 2010; Parnetti et al., 2012).
On the contrary, CSF t-Tau showed poor accuracy in prediction of MCI
conversion to AD dementia (Fig. 2; Table 2). Tau CSF levels may be
abnormally increased in several neurodegenerative disorders and their
relationship with AD and FTD brain pathology is still not fully under-
stood (van Harten et al., 2011).
Another crucial point concerns those patients with intermediate CSF
values, often close to cut-oﬀ, who cannot be assigned neither to the
‘normal’ nor to the entirely pathological categories. In these cases, the
adoption of a dichotomous classiﬁcation for CSF biomarkers might
produce an increased number of false positive or false negative, leading
to serious diagnostic misclassiﬁcations (Lewczuk et al., 2015). Con-
sistently, in our cohort, the use of the Erlangen Score algorithm
Table 3
Contingency table for the concordance between FDG-PET SPM and CSF classiﬁcation.
CSF FDG-PET SPM Classiﬁcation
AD FTD DLB Negative Total
Aβ42 Neg 11 17* 0 10 38
Pos 32* 0 1 9 42
t-Tau Neg 18 11 0 16 45
Pos 25 6 1 3 35
p-Tau Neg 11 12* 1 11 35
Pos 32 5 0 8 45
Erlangen Score 0 1 10* 0 7 18
1 3 1 0 2 6
2 16 6 0 5 27
3 7 0 0 2 9
4 16 0 1 3 20
Abbreviations: AD=Alzheimer's disease, FTD=Frontotemporal dementia,
DLB=dementia with Lewy bodies, Neg= negative, Pos=positive. Statistical diﬀer-
ences were assessed performing Chi-square analysis.
* Signiﬁcance at p < 0.05.
Fig. 1. Concordance between baseline CSF dichotomous values and FDG-PET SPM clas-
siﬁcation. For each of the three FDG-PET based categories (AD, FTD and negative pat-
terns), the percentage of subjects with positive CSF assessment is reported. CSF positivity
for Aβ42, t-Tau and p-Tau is highly prevalent among MCI with an AD FDG-PET pattern at
baseline. A minor portion of FTD patients show increased t-Tau and p-Tau levels. Aβ42
positivity characterize also ca. half of the MCI with a negative FDG-PET pattern.
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(Lewczuk et al., 2009) with ﬁve discrete CSF levels outperformed the
dichotomous classiﬁcation. Namely, an Erlangen Score > 2 predicted
AD dementia conversion with an AUC of 0.81, thus being more precise
as compared to the standard dichotomous division (AUC=0.68).
However, the Erlangen Score classiﬁcation still provided high per-
centages of false positives, i.e. cases with high scores (3 and 4) with no
conversion at follow-up, lowering the speciﬁcity of the CSF biomarkers.
We hypothesize that, for some of these cases, a longer follow-up might
be needed in order to capture the conversion; further, the false positives
might be accounted for by the presence of incidental amyloidosis as
previously shown (Iaccarino et al., 2017; Jansen et al., 2015). This last
point is also strongly supported by coexistence of pathological CSF
values for Aβ42 with negative FDG-PET-SPM maps. Notably, aiding the
intermediate Erlangen scores (1–3 range) by means of FDG-PET-SPM
classiﬁcation positively impacted on the speciﬁcity levels. In addition,
the FDG-PET-SPM classiﬁcation seems to be particularly relevant in
aiding better identiﬁcation of cases with possible non-amyloid-based
neurodegeneration (Perani, 2014).
FDG-PET-SPM classiﬁcation was the most accurate biomarker
(Fig. 2), able to correctly diﬀerentiate subjects who converted to AD
dementia or to other dementias (FTD and DLB) from those who re-
mained stable or reverted to normal cognition. FDG-PET imaging, as a
biomarker of local synaptic dysfunction, can early recognize disease-
speciﬁc alterations in neurodegenerative diseases (Caminiti et al., 2017;
Cerami et al., 2015; Iaccarino et al., 2017; Perani, 2013, 2014; Perani
et al., 2016; Teune et al., 2010).
First, these ﬁndings are consistent with the current literature on AD
diagnostic strategies, that shows higher accuracy for FDG-PET as
compared to other biomarkers (Bloudek et al., 2011; Dukart et al.,
2015; Fellgiebel et al., 2007; Iaccarino et al., 2017; Landau et al., 2010;
Perani et al., 2016; Robb et al., 2017; Shaﬀer et al., 2013; Yuan et al.,
2009). Of note, a recent study on the prognostic value of the NIA-AA
(McKhann et al., 2011b), IWG-2 and IWG-1 criteria (Dubois et al., 2007,
2014), showed that classiﬁcation based on the NIA-AA criteria for AD
dementia diagnosis, in which amyloid PET and FDG-PET biomarkers
are considered, reached the highest prediction accuracy in a clinical
setting (Vos et al., 2015). Second, this is the ﬁrst study, in a large MCI
samples, demonstrating the high value of FDG-PET with a validated
voxel-wise analysis for the assessment of the risk of progression to
diﬀerent dementia conditions, considering the very limited evidence in
previous literature (Cerami et al., 2015; Chiba et al., 2013; Fujishiro
et al., 2013; Perani et al., 2016). Third, a crucial evidence in favour of
the FDG-PET-SPM usefulness is its exclusionary role. Sixteen out of 19
negative FDG-PET cases did not convert to any dementia or even re-
verted to normal cognition. A negative FDG-PET-SPM pattern should
strongly suggest reconsidering a diagnosis of neurodegenerative disease
(Lo et al., 2011). High speciﬁcity and low negative LR value mean that a
negative or normal scan in the presence of the suspicion of dementia
makes the diagnosis of a neurodegenerative disease very unlikely
(Fig. 2). On the contrary, the CSF measures showed normal values in
only half of the stable or reverter cases, thus conﬁrming the funda-
mental value of FDG-PET in excluding underlying neurodegenerative
process in the MCI stage as compared to the other biomarkers.
Despite most MCI subjects presenting patterns of hypometabolism at
Fig. 2. Positive and negative likelihood ratio (LR+ and LR−) for correct classiﬁcation of MCI subjects converting to AD dementia.
LR+>5 indicates that the biomarker positive classiﬁcation is associated with the disease occurrence. LR−<0.2 indicates a relevant association between the negative biomarker
classiﬁcation and the absence of the dementia condition at follow up. LR values are represented on a logarithmic scale.
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baseline progressed to dementia, a proportion of them remained stable
(14 out of 61, 23%) (Table 2). In these cases, as aforementioned, a
longer clinical follow-up would be necessary to ascertain the eventual
conversion to dementia.
The combined use of FDG-PET and CSF Aβ42 biomarkers agreed in
predicting conversion to AD dementia at follow-up (Fig. 1; Table 3). In
addition, FDG-PET-SPM FTD patterns were associated with normal
values of CSF Aβ42 in all subjects (Fig. 1; Table 3).
MCI subjects with FDG-PET-SPM patterns suggestive of typical or
atypical AD variants did not diﬀer in CSF biomarker proﬁles, con-
ﬁrming that CSF measures are similar across diﬀerent AD variants
(Ossenkoppele et al., 2015; Seguin et al., 2011; Warren et al., 2012),
thus not providing a ﬁne-grained diﬀerentiation (see Supplementary
Fig. 2). At diﬀerence with CSF, the hypometabolism patterns detected
by FDG-PET-SPM classiﬁcation at the single-subject level were sug-
gestive of diﬀerent AD variants (see Supplementary Fig. 1), supporting
also a more precise prodromal diﬀerential diagnosis (Bohnen et al.,
2012; Perani et al., 2014b). Thanks to the ability to capture disease-
speciﬁc patterns, FDG-PET hypometabolism has been included as a
supportive feature in the clinical/research diagnostic criteria of mul-
tiple neurodegenerative conditions (Armstrong et al., 2013; Gorno-
Tempini et al., 2011; Litvan et al., 1996; McKeith et al., 2017; McKhann
et al., 2011a; Rascovsky et al., 2011). Overall, FDG-PET represents a
crucial biomarker for the classiﬁcation scheme in dementia.
In the up-to-date literature, the predictive power of FDG-PET in MCI
conversion to AD dementia varied widely and ranged from 25% to
100% for sensitivity and from 15% to 100% for speciﬁcity (Anchisi
et al., 2005; Arbizu et al., 2013; Chen et al., 2016; Chételat et al., 2003;
Landau et al., 2010; Ossenkoppele et al., 2013; Perani et al., 2014a,
2016). As also highlighted by the EANM reply to the Cochrane review
(Smailagic et al., 2015), the variability observed in the diﬀerent FDG-
PET studies, and the low accuracy obtained in the prediction of MCI
progression to dementia, might be caused by speciﬁc technical issues
(e.g. poorer sensitivity and lower spatial resolution of PET scanners and
small controls group for the statistical comparison), and, crucially, by
the lack of adequate biomarker quantiﬁcation (Morbelli et al., 2015).
Notably, we report high prognostic accuracy of the FDG-PET assess-
ment that could be traced back to the optimized features of the SPM
single-subject procedure, namely the use of i) dementia-speciﬁc tem-
plate for normalization of FDG-PET images, and ii) large normal dataset
for statistical comparisons at the individual level (Della Rosa et al.,
2014; Perani et al., 2014a). Speciﬁcity and sensitivity values for both
early and diﬀerential diagnosis of dementia signiﬁcantly increase in
clinical settings when semi-quantitative approaches are used (Perani
et al., 2014b).
5. Conclusions
An early and diﬀerential diagnosis of neurodegenerative dementias
is essential to improve patient management and clinical trial design.
Biomarkers can help to correctly select the candidates for clinical trials
and to plan eﬀective rehabilitative programmes, with an overall im-
provement of patients' and caregivers' quality of life and with public
costs saving. The appropriate use of PET tracers is crucial for a prompt
diagnosis and targeted evaluation of newly developed drugs aimed at
slowing or preventing dementia.
The fundamentals of FDG-PET are well established and are based on
extensively explored molecular mechanisms (Perani, 2014). Various
neuropathological events can contribute to synaptic dysfunction in
neurodegenerative diseases, e.g. altered intracellular signalling cas-
cades, mitochondria bioenergetics, impaired neurotransmitter release,
and proteinopathies (Kato et al., 2016; Perani, 2014). Though these
events can be localized, they can trigger long-distance alterations with
consistent disease-speciﬁc patterns that are accurately detected by FDG-
PET (Caminiti et al., 2017; Cerami et al., 2016, 2017; Iaccarino et al.,
2015; Perani, 2014; Perani et al., 2016; Teipel et al., 2015; Teune et al.,
2010), even before manifest brain atrophy (Bateman et al., 2012;
Chételat et al., 2008; Perani, 2014). In the last years, growing evidence
on the positive diagnostic and prognostic value of FDG-PET fostered the
scientiﬁc community to promote the relevance of cerebral FDG-PET in
the diagnostic work-up in neurodegenerative diseases.
The use of topographical (FDG-PET) and CSF measures, tailored on
individual cases and measured with validated approaches can re-
markably improve early diﬀerential diagnosis and prediction or exclu-
sion of progression risk to dementia in MCI subjects. In the future,
optimized automated methods for CSF quantiﬁcation might reduce
inter-centres analytical variability (Bittner et al., 2016). This will in-
crease reliability and comparability of CSF quantiﬁcation when per-
formed across diﬀerent centres (Ewers et al., 2015; Mattsson and
Zetterberg, 2010) and narrow the “grey zone” of biomarker uncertainty
given by analytical variability (Simonsen et al., 2017).
This study has some limitations. First, a longer clinical-neu-
ropsychological follow-up is certainly needed in non-converter subjects
with CSF measures and FDG-PET SPM maps classiﬁcation indicative of
underling neurodegeneration.
Both CSF and FDG-PET data were considered in the follow-up di-
agnostic work-up. This may have in part contributed to the agreement
between biomarkers and clinical diagnosis at follow-up. The high
consistency of FDG-PET biomarker' performance when using CDR as an
alternative outcome, indicates an overall robustness of its predictive
value. Another limitation for this and other similar studies is the lack of
post-mortem neuropathological conﬁrmation of the ﬁnal diagnosis.
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